
    
      OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the
      larynx treated with autogenous vaccine derived from each patient's own tumor.

      OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously
      weekly for 20 weeks.

      PROJECTED ACCRUAL: Not specified
    
  